Parstatin (mouse)

Parstatin (mouse) Suppliers list
Company Name: 3B Pharmachem (Wuhan) International Co.,Ltd.  
Tel: 18930552037
Email: 3bsc@sina.com
Company Name: Creative Peptides   
Tel:
Email: info@creative-peptides.com
Company Name: Chengdu Youngshe Chemical Co., Ltd.  
Tel: +86-17380623303
Email: Caroline@youngshechem.com
Company Name: Hangzhou Peptidego Biotech Co.,Ltd.  
Tel: 0571-87213919 15967184799
Email: Eric@peptidego.com
Company Name: BOC Sciences  
Tel: 16314854226; +8616314854226
Email: inquiry@bocsci.com
Parstatin (mouse) Basic information
Product Name:Parstatin (mouse)
Synonyms:Parstatin (mouse);MGPRRLLIVALGLSLCGPLLSSRVPMSQPESERTDATVNPR;Parstatin (mouse) TFA
CAS:1065756-01-5
MF:C189H326N58O57S3
MW:0
EINECS:
Product Categories:
Mol File:Mol File
Parstatin (mouse) Structure
Parstatin (mouse) Chemical Properties
storage temp. Store at -20°C
form Powder
color White to off-white
Water Solubility Soluble to 1 mg/ml in water
Safety Information
MSDS Information
Parstatin (mouse) Usage And Synthesis
DescriptionCell-permeable peptide cleaved from protease-activated receptor 1 (PAR1) upon receptor activation. Attenuates endothelial cell migration and proliferation (IC50~ 20μM), and induces cell cycle arrest. Promotes activation of caspase-3 and exhibits pro-apoptotic activityin vitro. Inhibits angiogenesis and exhibits cardioprotective activityin vivo.
UsesParstatin(mouse), a cell-penetrating PAR-1 thrombin receptor agonist peptide, is a potent inhibitor of angiogenesis[1][2].
in vivo

Parstatin (single dose, 1-25 μg/kg, iv) administered prior to ischaemia confers immediate cardioprotection by recruiting the Gi-protein activation pathway including p38 MAPK, ERK1/2, NOS, and KATP channels. Parstatin exerts effects on both the cardiomyocytes and the coronary circulation to induce cardioprotection. This suggests a potential therapeutic role of parstatin in the treatment of cardiac injury resulting from ischaemia and reperfusion[1].

Animal Model:Male Sprague–Dawley rats at 8 weeks of age (250-300 g)[1].
Dosage:1-25 μg/kg.
Administration:IV injected 15 min prior to ischaemia.
Result:A significant decrease in infarct size was detected with the 5-15 μg/kg doses with 10 μg/kg as the optimal dose. These hearts had an infarct size of 46 ± 3% of the area at risk, which is a 26% reduction in infarct size compared with the control.
References[1] Panagiota Zania, et al. Parstatin, the Cleaved Peptide on Proteinase-Activated Receptor 1 Activation, Is a Potent Inhibitor of Angiogenesis. J Pharmacol Exp Ther. 2009 Feb;328(2):378-89. DOI:10.1124/jpet.108.145664
[2] Jennifer L Strande, et al. Parstatin: A Cryptic Peptide Involved in Cardioprotection After Ischaemia and Reperfusion Injury. Cardiovasc Res. 2009 Jul 15;83(2):325-34. DOI:10.1093/cvr/cvp122
Parstatin (mouse) Preparation Products And Raw materials
Tag:Parstatin (mouse)(1065756-01-5) Related Product Information
Parstatin (human) Trypsin RENIN Protein, HUMAN (HEK293, HIS) 2-(2-Furoyl)-Leu-Ile-Gly-Arg-Leu-Orn-NH2 (S)-2-(6-bromobenzo[d][1,3]dioxol-5-yl)-N-(4-cyanophenyl)-1-(1-cyclohexylethyl)-1H-benzo[d]imidazole-5-carboxamide H-Ser-Leu-Ile-Gly-Arg-Leu-NH2